Ignite Creation Date:
2025-12-24 @ 3:35 PM
Ignite Modification Date:
2026-02-26 @ 2:14 AM
Study NCT ID:
NCT02003092
Status:
TERMINATED
Last Update Posted:
2020-01-06
First Post:
2013-11-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'submissionInfos': [{'resetDate': '2020-07-02', 'releaseDate': '2020-06-15'}], 'estimatedResultsFirstSubmitDate': '2020-06-15'}}, 'conditionBrowseModule': {'meshes': [{'id': 'D064726', 'term': 'Triple Negative Breast Neoplasms'}, {'id': 'D009362', 'term': 'Neoplasm Metastasis'}, {'id': 'D012008', 'term': 'Recurrence'}], 'ancestors': [{'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D009385', 'term': 'Neoplastic Processes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D020969', 'term': 'Disease Attributes'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000606305', 'term': 'RX-5902'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 18}}, 'statusModule': {'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2013-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-01', 'completionDateStruct': {'date': '2019-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-01-03', 'studyFirstSubmitDate': '2013-11-15', 'studyFirstSubmitQcDate': '2013-12-03', 'lastUpdatePostDateStruct': {'date': '2020-01-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-12-06', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2019-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'phosphorylated P68 by IHC', 'timeFrame': 'baseline and 8 weeks'}, {'measure': 'Tumor burden response (Phase 2)', 'timeFrame': 'Baseline and at 4, 8, 12, 16 and 24 weeks'}], 'primaryOutcomes': [{'measure': 'Incidence of dose limiting toxicities (DLTs) (Phase 1)', 'timeFrame': 'after 4 weeks of treatment with RX-5902'}, {'measure': 'Progression free survival rate and/or overall clinical response rate (Phase 2)', 'timeFrame': '16 weeks of treatment with RX-5902'}], 'secondaryOutcomes': [{'measure': 'Area under the plasma concentration versus time curve (AUC) of RX-5902', 'timeFrame': 'predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8 hrs after the first dose'}, {'measure': 'Changes in tumor size mm', 'timeFrame': 'baseline and 24 weeks'}, {'measure': 'Time to progression (Phase 2)', 'timeFrame': 'Baseline and at 4, 8, 12, 16 and 24 weeks'}, {'measure': 'Duration of response (Phase 2)', 'timeFrame': 'Baseline and at 4, 8, 12, 16 and 24 weeks'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '6 months'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Metastatic', 'Rexahn', 'Phase 1', 'Triple Negative Breast Cancer', 'Phase 2', 'Relapsed'], 'conditions': ['Solid Tumor', 'Triple Negative Breast Cancer']}, 'descriptionModule': {'briefSummary': 'The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.', 'detailedDescription': 'In this dose-finding, open-label, single-agent study of RX-5902, subjects will be treated for up to 6 cycles of therapy. RX-5902 will be administered orally daily for 3 weeks followed by 1 week of rest in each cycle. All subjects will be followed for at least 30 days after the last dose of study agent for safety.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Male and female who are 18 yrs or older\n* Histologically confirmed triple negative breast cancer that are refractory, intolerant, or ineligible to receive approved standard therapies\n* Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST)\n* Life expectancy of at least 3 months\n* Able to swallow capsules\n* Provide written informed consent\n\nExclusion Criteria:\n\n* Primary brain tumor or active brain metastasis\n* Not recovered to less than or equal to Grade 1 toxicities (except Grade 2 alopecia or neuropathy) associated with previous cancer therapies\n* Any other cancer treatments within 2 weeks of planned study treatment\n* History of any medical or psychiatric condition or addictive disorder, or lab abnormality that in the opinion of the investigator, may increase risks or may interfere with study participation or interpretation of study results\n* History of clinically significant GI bleed, intestinal obstruction, or GI perforation within 6 months of study dose\n* Uncontrolled diabetes\n* History of long QT syndrome or clinically significant cardiac arrhythmias (except stable atrial fibrillation)\n* Myocardial infarction within 6 months of study dose\n* Active infection requiring IV antibiotics within 2 weeks of study dose\n* History of Hepatitis B, C, or HIV\n* Use of potent inhibitor or inducer of CYP3A4/3A5 within 14 days of planned study treatment or expected requirement for use of such a drug during study\n* Use of a potent inhibitor or inducer of drug transporters or conjugating enzymes within 14 days prior to planned study treatment or expected requirement for use of such a drug during study\n* Receiving other investigational agents or not yet completed 30 days since completion of an investigational study\n* Pregnant, planning a pregnancy, or breast feeding\n* Male or female not willing to use adequate contraceptive precautions during the study period. Females must either be surgically sterile, post-menopausal for 12 months, or use a contraceptive approved by sponsor.\n* Unwilling or unable to provide written informed consent, comply with study requirements, or be available for follow-up assessments'}, 'identificationModule': {'nctId': 'NCT02003092', 'briefTitle': 'RX-5902 Treatment of Subjects With Triple Negative Breast Cancer', 'organization': {'class': 'INDUSTRY', 'fullName': 'Rexahn Pharmaceuticals, Inc.'}, 'officialTitle': 'A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors', 'orgStudyIdInfo': {'id': 'RX-5902-P1-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'RX-5902', 'description': 'RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.', 'interventionNames': ['Drug: RX-5902']}], 'interventions': [{'name': 'RX-5902', 'type': 'DRUG', 'otherNames': ['Supinoxin™'], 'description': 'escalating doses (mg)', 'armGroupLabels': ['RX-5902']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85724', 'city': 'Tucson', 'state': 'Arizona', 'country': 'United States', 'facility': 'Rexahn site', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'Rexahn Site', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '60637', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rexahn site', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '48202', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Rexahn Site', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Rexahn Site', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '10065', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Rexahn Site', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '29605', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Rexahn Site', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '22031', 'city': 'Arlington', 'state': 'Virginia', 'country': 'United States', 'facility': 'Rexahn site', 'geoPoint': {'lat': 38.88101, 'lon': -77.10428}}], 'overallOfficials': [{'name': 'Ely Benaim, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Rexahn Pharmaceuticals, Inc.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Rexahn Pharmaceuticals, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}, 'annotationSection': {'annotationModule': {'unpostedAnnotation': {'unpostedEvents': [{'date': '2020-06-15', 'type': 'RELEASE'}, {'date': '2020-07-02', 'type': 'RESET'}], 'unpostedResponsibleParty': 'Rexahn Pharmaceuticals, Inc.'}}}}